Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zynerba Pharmaceuticals, Inc.ZYNE · Entity 109058 | 10% owner | May 30, 2018 | May 31, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zynerba Pharmaceuticals, Inc.
Report date May 30, 2018 · Filed May 31, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,500,000 |
Reported balance
After 2018-05-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-05-30 · Purchase · Acquired 5,885 · Balance 1,500,000 F1: Includes 80,467 shares transferred by Broadband Capital Management LLC ("BCM") to Reporting Person for no consideration. The Reporting Person was the Chairman and member of BCM. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 80,467 shares transferred by Broadband Capital Management LLC ("BCM") to Reporting Person for no consideration. The Reporting Person was the Chairman and member of BCM.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Immunome Inc.
Report date October 02, 2023 · Filed October 03, 2023
Section 16 reporting ended · disclosed 2023-10-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,071,172 |
Reported balance
After 2023-10-02 transaction · row 1
1 source rowRow 1 · 2023-10-02 · Grant · Acquired 253,806 · Balance 1,071,172 F1: The shares were issued to the Reporting Person pursuant to the closing of the transactions contemplated by that certain Subscription Agreement, dated as of June 29, 2023, by and among the Reporting Person and the Issuer and in connection with the closing of to the transactions contemplated by that certain Agreement and Plan of Merger and Reorganization, dated as of June 29, 2023, by and among the Issuer, Morphimmune Inc., a Delaware corporation, and Ibiza Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Issuer. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 208,742 |
Reported balance
Holding disclosure · report date 2023-10-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 208,742 F2: The shares are held by Broadband Capital Investments LLC ("Broadband"). The reporting person is managing member of Broadband and has voting and investment power with respect to shares held by Broadband. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were issued to the Reporting Person pursuant to the closing of the transactions contemplated by that certain Subscription Agreement, dated as of June 29, 2023, by and among the Reporting Person and the Issuer and in connection with the closing of to the transactions contemplated by that certain Agreement and Plan of Merger and Reorganization, dated as of June 29, 2023, by and among the Issuer, Morphimmune Inc., a Delaware corporation, and Ibiza Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Issuer.
F2: The shares are held by Broadband Capital Investments LLC ("Broadband"). The reporting person is managing member of Broadband and has voting and investment power with respect to shares held by Broadband.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2023 Filed Oct 3, 2023 21:50 UTC | Immunome Inc. IMNM · Entity 4219 | GrantCommon Stock | 253,806 | $5.91 | $1,499,993.46 |
DisclosureSEC source: 0001104659-23-106486 · tm2327557-1_4seq1.xml · nonDerivative · entry 1 RAPP MICHAEL · CIK 0001405685 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,071,172 F1 · shares: The shares were issued to the Reporting Person pursuant to the closing of the transactions contemplated by that certain Subscription Agreement, dated as of June 29, 2023, by and among the Reporting Person and the Issuer and in connection with the closing of to the transactions contemplated by that certain Agreement and Plan of Merger and Reorganization, dated as of June 29, 2023, by and among the Issuer, Morphimmune Inc., a Delaware corporation, and Ibiza Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Issuer. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:05 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $4.84 | $0.00 |
DisclosureSEC source: 0001104659-23-070422 · tm2318426-3_4seq.xml · derivative · entry 1 RAPP MICHAEL · CIK 0001405685 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2033-06-08 F1 · derivative.exercise_date: The shares subject to the options shall vest 25% every quarter after the grant date. Read SEC document |
| January 15, 2023 Filed Jan 17, 2023 11:26 UTC | Immunome Inc. IMNM · Entity 4219 | GrantCommon Stock | 17,500 | $4.00 | $70,000.00 |
DisclosureSEC source: 0001104659-23-004001 · tm233517-1_4seq1.xml · nonDerivative · entry 1 RAPP MICHAEL · CIK 0001405685 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 817,366 F1 · price: The shares of Common Stock were issued to the Reporting Person pursuant to the Issuer's 2020 Equity Compensation Plan in lieu of the non-employee director board and committee cash retainers of $70,000 in the aggregate owed to the Reporting Person for service on the board of directors in 2022. Read SEC document |
| June 16, 2022 Filed Jun 21, 2022 22:04 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 6,500 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0001104659-22-073097 · tm2218674-5_4seq1.xml · derivative · entry 1 RAPP MICHAEL · CIK 0001405685 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2032-06-16 F1 · derivative.exercise_date: The shares subject to the options shall vest 25% every quarter after the grant date. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 11:28 UTC | Immunome Inc. IMNM · Entity 4219 | PurchaseCommon Stock | 25,962 | $19.96 | $518,201.52 |
DisclosureSEC source: 0001104659-21-115280 · tm2127437-3_4seq1.xml · nonDerivative · entry 1 RAPP MICHAEL · CIK 0001405685 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 208,742 F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $19.80 to $20.00, inclusive. Upon request of the SEC staff or the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: The shares are held by Broadband Capital Investments LLC ("Broadband"). The reporting person is managing member of Broadband and has voting and investment power with respect to shares held by Broadband. Read SEC document |
| September 10, 2021 Filed Sep 13, 2021 11:52 UTC | Immunome Inc. IMNM · Entity 4219 | PurchaseCommon Stock | 15,500 | $17.85 | $276,675.00 |
DisclosureSEC source: 0001104659-21-114881 · tm2127437-2_4seq1.xml · nonDerivative · entry 3 RAPP MICHAEL · CIK 0001405685 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 182,780 F4 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $17.25 to $18.08, inclusive. Upon request of the SEC staff or the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: The shares are held by Broadband Capital Investments LLC ("Broadband"). The reporting person is managing member of Broadband and has voting and investment power with respect to shares held by Broadband. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 11:52 UTC | Immunome Inc. IMNM · Entity 4219 | PurchaseCommon Stock | 22,280 | $18.46 | $411,288.80 |
DisclosureSEC source: 0001104659-21-114881 · tm2127437-2_4seq1.xml · nonDerivative · entry 2 RAPP MICHAEL · CIK 0001405685 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 167,280 F3 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $17.88 to $18.75, inclusive. Upon request of the SEC staff or the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: The shares are held by Broadband Capital Investments LLC ("Broadband"). The reporting person is managing member of Broadband and has voting and investment power with respect to shares held by Broadband. Read SEC document |
| September 09, 2021 Filed Sep 13, 2021 11:52 UTC | Immunome Inc. IMNM · Entity 4219 | PurchaseCommon Stock | 8,170 | $17.44 | $142,484.80 |
DisclosureSEC source: 0001104659-21-114881 · tm2127437-2_4seq1.xml · nonDerivative · entry 1 RAPP MICHAEL · CIK 0001405685 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 145,000 F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $16.76 to $17.65, inclusive. Upon request of the SEC staff or the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: The shares are held by Broadband Capital Investments LLC ("Broadband"). The reporting person is managing member of Broadband and has voting and investment power with respect to shares held by Broadband. Read SEC document |
| May 28, 2021 Filed Jun 2, 2021 00:04 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $20.92 | $0.00 |
DisclosureSEC source: 0001104659-21-075262 · tm2118079-5_4seq1.xml · derivative · entry 1 RAPP MICHAEL · CIK 0001405685 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 3,750 shares Expires 2031-05-28 F1 · derivative.exercise_date: The shares subject to the option shall vest 25% every quarter after the grant date. Read SEC document |
| May 26, 2021 Filed May 27, 2021 01:31 UTC | Immunome Inc. IMNM · Entity 4219 | PurchaseCommon Stock | 2,300 | $18.94 | $43,562.00 |
DisclosureSEC source: 0001104659-21-072620 · tm2117684-4_4seq1.xml · nonDerivative · entry 3 RAPP MICHAEL · CIK 0001405685 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 136,830 F5 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $18.88 to $18.95, inclusive. Upon request of the SEC staff or the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: The shares are held by Broadband. Read SEC document |
| May 25, 2021 Filed May 27, 2021 01:31 UTC | Immunome Inc. IMNM · Entity 4219 | PurchaseCommon Stock | 19,303 | $18.32 | $353,630.96 |
DisclosureSEC source: 0001104659-21-072620 · tm2117684-4_4seq1.xml · nonDerivative · entry 2 RAPP MICHAEL · CIK 0001405685 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 134,530 F4 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $18.15 to $18.40, inclusive. Upon request of the SEC staff or the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price. F3 · ownership.nature: The shares are held by Broadband. Read SEC document |
| May 24, 2021 Filed May 27, 2021 01:31 UTC | Immunome Inc. IMNM · Entity 4219 | PurchaseCommon Stock | 31,895 | $18.38 | $586,230.10 |
DisclosureSEC source: 0001104659-21-072620 · tm2117684-4_4seq1.xml · nonDerivative · entry 1 RAPP MICHAEL · CIK 0001405685 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 115,227 F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $18.25 to $18.51, inclusive. Upon request of the SEC staff or the issuer, the reporting person will provide full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 83,332 shares previously held directly by the reporting person which were transferred to Broadband Capital Investments LLC ("Broadband"). The reporting person is managing member of Broadband and has voting and investment power with respect to shares held by Broadband. F3 · ownership.nature: The shares are held by Broadband. Read SEC document |
| November 03, 2020 Filed Nov 6, 2020 01:05 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $11.38 | $0.00 |
DisclosureSEC source: 0001104659-20-122023 · a4.xml · derivative · entry 1 RAPP MICHAEL · CIK 0001405685 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2030-11-03 F1 · security: One-twelfth (1/12th) of the shares subject to the option shall vest on February 3, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest every three months thereafter. F1 · derivative.exercise_date: One-twelfth (1/12th) of the shares subject to the option shall vest on February 3, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest every three months thereafter. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 22:16 UTC | Immunome Inc. IMNM · Entity 4219 | ConversionWarrant (right to buy) · Derivative | 166,666 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054318 · doc4.xml · derivative · entry 6 RAPP MICHAEL · CIK 0001405685 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,666 Underlying: Common Stock · 166,666 shares Expires 2023-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Each share of Series A Convertible Preferred Stock underlying this warrant automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 22:16 UTC | Immunome Inc. IMNM · Entity 4219 | ConversionWarrant (right to buy) · Derivative | 166,666 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054318 · doc4.xml · derivative · entry 5 RAPP MICHAEL · CIK 0001405685 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Series A Convertible Preferred Stock · 166,666 shares Expires 2023-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: Each share of Series A Convertible Preferred Stock underlying this warrant automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F4 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 22:16 UTC | Immunome Inc. IMNM · Entity 4219 | ConversionSeries A Convertible Preferred Stock · Derivative | 555,554 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054318 · doc4.xml · derivative · entry 4 RAPP MICHAEL · CIK 0001405685 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 555,554 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 22:16 UTC | Immunome Inc. IMNM · Entity 4219 | PurchaseCommon Stock | 83,332 | $12.00 | $999,984.00 |
DisclosureSEC source: 0001209191-20-054318 · doc4.xml · nonDerivative · entry 2 RAPP MICHAEL · CIK 0001405685 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,886 Read SEC document |
| October 06, 2020 Filed Oct 8, 2020 22:16 UTC | Immunome Inc. IMNM · Entity 4219 | ConversionCommon Stock | 555,554 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-054318 · doc4.xml · nonDerivative · entry 1 RAPP MICHAEL · CIK 0001405685 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 555,554 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date. Read SEC document |
| May 30, 2018 Filed May 31, 2018 13:26 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | PurchaseCommon Stock | 5,885 | $10.45 | $61,498.25 |
DisclosureSEC source: 0001615774-18-004593 · s110552_form4.xml · nonDerivative · entry 1 RAPP MICHAEL · CIK 0001405685 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500,000 F1 · balance_after: Includes 80,467 shares transferred by Broadband Capital Management LLC ("BCM") to Reporting Person for no consideration. The Reporting Person was the Chairman and member of BCM. Read SEC document |
| May 02, 2018 Filed May 2, 2018 21:38 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | PurchaseCommon Stock | 15,000 | $10.46 | $156,945.00 |
DisclosureSEC source: 0001615774-18-003217 · s109943_form4.xml · nonDerivative · entry 1 RAPP MICHAEL · CIK 0001405685 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,494,115 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.39 to $10.50, inclusive. The reporting person undertakes to provide to Zynerba, any security holder of Zynerba, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F2 · balance_after: Includes 80,467 shares transferred by Broadband Capital Management LLC ("BCM") to Reporting Person for no consideration. The Reporting Person was the Chairman and member of BCM. Read SEC document |
| March 22, 2018 Filed Mar 23, 2018 13:30 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | PurchaseCommon Stock | 10,000 | $9.28 | $92,790.00 |
DisclosureSEC source: 0001615774-18-002065 · s109443_form4.xml · nonDerivative · entry 1 RAPP MICHAEL · CIK 0001405685 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,479,115 F1 · balance_after: Includes 80,467 shares transferred by Broadband Capital Management LLC ("BCM") to Reporting Person for no consideration. The Reporting Person was the Chairman and member of BCM. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 11:05 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | PurchaseCommon Stock | 15,000 | $12.99 | $194,847.00 |
DisclosureSEC source: 0001615774-18-000031 · s108608_form4.xml · nonDerivative · entry 1 RAPP MICHAEL · CIK 0001405685 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,469,115 F1 · balance_after: Includes 80,467 shares transferred by Broadband Capital Management LLC ("BCM") to Reporting Person for no consideration. The Reporting Person was the Chairman and member of BCM. Read SEC document |
| October 23, 2017 Filed Oct 23, 2017 23:25 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | PurchaseCommon Stock | 25,745 | $9.94 | $255,794.60 |
DisclosureSEC source: 0001615774-17-005848 · s107828_rapp.xml · nonDerivative · entry 3 RAPP MICHAEL · CIK 0001405685 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,454,115 F1 · balance_after: Includes 80,467 shares transferred by Broadband Capital Management LLC ("BCM") to Reporting Person for no consideration. The Reporting Person was the Chairman and member of BCM. Read SEC document |
| October 20, 2017 Filed Oct 23, 2017 23:25 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | PurchaseCommon Stock | 30,000 | $9.78 | $293,538.00 |
DisclosureSEC source: 0001615774-17-005848 · s107828_rapp.xml · nonDerivative · entry 2 RAPP MICHAEL · CIK 0001405685 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,428,370 F1 · balance_after: Includes 80,467 shares transferred by Broadband Capital Management LLC ("BCM") to Reporting Person for no consideration. The Reporting Person was the Chairman and member of BCM. Read SEC document |
| October 19, 2017 Filed Oct 23, 2017 23:25 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | PurchaseCommon Stock | 44,255 | $9.59 | $424,405.45 |
DisclosureSEC source: 0001615774-17-005848 · s107828_rapp.xml · nonDerivative · entry 1 RAPP MICHAEL · CIK 0001405685 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,398,370 F1 · balance_after: Includes 80,467 shares transferred by Broadband Capital Management LLC ("BCM") to Reporting Person for no consideration. The Reporting Person was the Chairman and member of BCM. Read SEC document |
| December 29, 2016 Filed Dec 30, 2016 02:54 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | PurchaseCommon Stock | 10,000 | $15.85 | $158,500.00 |
DisclosureSEC source: 0001144204-16-141808 · v455965_4.xml · nonDerivative · entry 1 RAPP MICHAEL · CIK 0001405685 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,354,115 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.